Literature DB >> 18224443

Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

José Cangiano1, Barbara A Centeno, Christopher R Garrett, William Cáceres, Ana de Jesús, Ji-Hyun Lee, Orestes Pavía, Richard Jove, Luis Báez, Daniel M Sullivan, Carlos A Muro-Cacho, Teresita Muñoz-Antonia.   

Abstract

Overexpression of the HER2/NEU gene is associated with aggressive behavior and poor prognosis in breast cancer, making the Her2/neu protein a directed-therapy target. Tumors of two Puerto Rican (PR) patients overexpressed Her2/neu and resulting partial clinical responses motivated us to compare Her2/neu expression in PR (n = 101) and Caucasian non-Hispanic (n = 95) patients. Immunohistochemistry of tumors showed overexpression of p-Stat3, Cyclin D1, and Her2/neu, compared to non-neoplastic mucosa. Her2/neu and EGF-R protein levels were statistically significantly different with higher levels of both proteins in the PR group. Importantly, Her2/neu expression was strong and diffuse in tumors with signet-ring morphology, while other histo-pathological subtypes showed higher intra-tumoral Her2/neu heterogeneity than typically observed in breast cancer. Targeted therapies in gastric cancer directed at EGF-R and Hers-2/neu pathways warrant further investigation. These therapies may be especially effective in PR patients and in patients with signet-ring cell morphologies with a dismal prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18224443      PMCID: PMC4467019          DOI: 10.1007/s10620-007-0118-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  52 in total

1.  Stomach and colon cancer mortality among Puerto Ricans in New York City at Puerto Rico.

Authors:  M Monk; M E Warshauer
Journal:  J Chronic Dis       Date:  1975-08

2.  Association of Helicobacter pylori infection with gastric cancer.

Authors:  G A Alexander; O W Brawley
Journal:  Mil Med       Date:  2000-01       Impact factor: 1.437

3.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors:  H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Authors:  Rohit Bhargava; William L Gerald; Allan R Li; Qiulu Pan; Priti Lal; Marc Ladanyi; Beiyun Chen
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

5.  Trends in cancer mortality in the Americas, 1970-2000.

Authors:  C Bosetti; M Malvezzi; L Chatenoud; E Negri; F Levi; C La Vecchia
Journal:  Ann Oncol       Date:  2005-01-24       Impact factor: 32.976

Review 6.  The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Authors:  J S Ross; B J McKenna
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.

Authors:  K Kono; H Naganuma; T Sekikawa; H Amemiya; A Takahashi; H Iizuka; Y Matsumoto
Journal:  Tumour Biol       Date:  2000 May-Jun

8.  Clinical implications of recent developments in gastric cancer pathology and epidemiology.

Authors:  P Correa
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

Review 9.  Monoclonal antibodies as effective therapeutic agents for solid tumors.

Authors:  Yuji Hinoda; Shigeru Sasaki; Tadao Ishida; Kohzoh Imai
Journal:  Cancer Sci       Date:  2004-08       Impact factor: 6.716

10.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

Authors:  S Uchino; H Tsuda; K Maruyama; T Kinoshita; M Sasako; T Saito; M Kobayashi; S Hirohashi
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

2.  Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.

Authors:  Hai-Zhen Dang; Yang Yu; Shun-Chang Jiao
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

3.  Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.

Authors:  Guangchao Li; Likun Zhao; Wei Li; Kexing Fan; Weizhu Qian; Sheng Hou; Hao Wang; Jianxin Dai; Huafeng Wei; Yajun Guo
Journal:  Oncotarget       Date:  2014-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.